In this context, GM-CSF secreting melanoma vaccines may serve to prime a patient’s immune system, whereas the addition of checkpoint blockade or other immune activating mechanisms may augment the anti-tumor response and potentiate clinical efficacy. This evidence concerns the gene CSF2 and neoplasm.